Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly's GLP-1 outdoes Novo Nordisk's
Eli Lilly's GLP-1 outdoes Novo Nordisk's in trial
Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly reported from the first head-to-head trial comparing the two blockbuster GLP-1 obesity drugs.
Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters.
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
1d
on MSN
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
4h
on MSN
Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments
Eli
Lilly
said it would invest $3 billion to expand a recently ... Zepbound and Mounjaro.
Lilly
’s rival,
Novo
...
2d
Exclusive: Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...
Benzinga Finance on MSN
3h
Weight Loss Drug Prescriptions Double In 2024 Despite High Costs
Prescription fills for weight loss drugs more than doubled in 2024 despite limited insurance coverage and high costs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback